WO2005120493A1 - Anticancer effect enhancer - Google Patents

Anticancer effect enhancer Download PDF

Info

Publication number
WO2005120493A1
WO2005120493A1 PCT/JP2005/011078 JP2005011078W WO2005120493A1 WO 2005120493 A1 WO2005120493 A1 WO 2005120493A1 JP 2005011078 W JP2005011078 W JP 2005011078W WO 2005120493 A1 WO2005120493 A1 WO 2005120493A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
patients
chemotherapy
once
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2005/011078
Other languages
English (en)
French (fr)
Other versions
WO2005120493A8 (en
Inventor
Hiroyasu Yasuda
Mutsuo Yamaya
Katsutoshi Nakayama
Hidetada Sasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Priority to JP2006551137A priority Critical patent/JP4729503B2/ja
Priority to DE602005018222T priority patent/DE602005018222D1/de
Priority to CN2005800271680A priority patent/CN101001623B/zh
Priority to US11/628,943 priority patent/US20080039521A1/en
Priority to EP05750803A priority patent/EP1778215B1/en
Publication of WO2005120493A1 publication Critical patent/WO2005120493A1/en
Anticipated expiration legal-status Critical
Publication of WO2005120493A8 publication Critical patent/WO2005120493A8/en
Priority to US12/318,061 priority patent/US8410175B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer.
  • hypoxic condition promotes the resistance of cancer cells to anticancer agent.
  • hypoxic condition promotes the resistance of cancer cells to anticancer agent.
  • the surviving rate is as high as two-fold or more even if the cancer cells are directly exposed to.the anticancer agent as compared with the case where they are exposed in normoxic condition provided that they are exposed in hypoxic condition.
  • Non-Patent Document 8 (DC Jenkins, IG Charles, LL Thomsen, DW Moss, LS Holmes, SA Baylis, P Rhodes, K Westmore, PC Emson, S Moncada.
  • Non-Patent Document 9 Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol . , 2001; 2: 149-156) , it is shown that NOS of a derived type participates in mutation of p53 of tumor of colon, lung and throat and that NO stimulates the growth of tumor via activation of cyclooxygenase-2 (COX-2) .
  • COX-2 cyclooxygenase-2
  • Non-Patent Document 1 it is shown that resistance of cancer cell line to anticancer agent induced by hypoxic condition is improved by a NO donor in an experiment using cultured cells and, although such a finding will be surely valuable for showing one direction for future research, it is not possible to conclude from such a finding that a NO donor has an action of shrinking the cancer tissues or an action of enhancing the effect of anticancer agent. So, it is all the more that, in human clinical medicine, a conclusion that a NO donor enhances the effect of anticancer agent is unable to be done and should not be done.
  • an anticancer agent which is used in chemotherapy where effect is enhanced by the concomitant use of a NO donor and its examples are antimetabolites exemplified by 5-fluorouracil, methotrexate, doxifluridine, tegafur, cytarabine and gemcitabine; alkylating agents exemplified by cyclophosphamide, ifosfamide, thiotepa, carboquone and nimustine hydrochloride; anticancer antibiotics exemplified by mitomycin, doxorubicin hydrochloride, amurubicin hydrochloride, pirarubicin hydrochloride, epirubicin hydrochloride, aclarubicin hydrochloride, mitoxantrone hydrochloride, bleomycin hydrochloride and peplomycin sulfate; microtubule-acting agents exemplified by docetaxel, paclitaxel, vincris
  • Example 1 A study of the effect of concomitant use of NO donors with anticancer agents on response to chemotherapy in patients with advanced non-small cell lung cancer in a prospective randomised controlled trial Characteristics of the subjects Sixty five patients with inoperable advanced non-small cell lung cancer (NSCLC) fit the following five criteria and were recruited in this study: (a) stage IIIB or stage IV; (b) no prior chemotherapy or radiotherapy; (c) good performance status: a performance status of 0-2 according to the Eastern Cooperative Oncology Group (ECOG) scale; (d) without brain metastasis; (e) adequate renal function, hepatic function, hematological function and cardiac function.
  • NSCLC inoperable advanced non-small cell lung cancer
  • MVP mitomycin C+vinorelbine+cisplatin
  • CDDP cisplatin
  • DOC docetaxel
  • VNR vinorelbine.
  • CR complete response
  • PR partial response
  • NC no change
  • PD progressive disease
  • NO nitric oxide
  • MVP mitomycin C+vinorelbine+cisplatin
  • CDDP cisplatin
  • DOC docetaxel
  • VNR vinorelbine.
  • the NO donor group as well as the control group showed rapid tumor growth compared with that in the chemotherapy group and the NO plus chemotherapy group.
  • the present invention is able to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer whereby it has an industrial applicability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2005/011078 2004-06-10 2005-06-10 Anticancer effect enhancer Ceased WO2005120493A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2006551137A JP4729503B2 (ja) 2004-06-10 2005-06-10 抗癌剤の奏効率増強剤
DE602005018222T DE602005018222D1 (https=) 2004-06-10 2005-06-10
CN2005800271680A CN101001623B (zh) 2004-06-10 2005-06-10 抗癌效果增强剂
US11/628,943 US20080039521A1 (en) 2004-06-10 2005-06-10 Anticancer Effect Enhancer
EP05750803A EP1778215B1 (en) 2004-06-10 2005-06-10 Anticancer effect enhancer
US12/318,061 US8410175B2 (en) 2004-06-10 2008-12-22 Anticancer effect enhancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004173174 2004-06-10
JP2004-173174 2004-06-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/628,943 A-371-Of-International US20080039521A1 (en) 2004-06-10 2005-06-10 Anticancer Effect Enhancer
US12/318,061 Division US8410175B2 (en) 2004-06-10 2008-12-22 Anticancer effect enhancer

Publications (2)

Publication Number Publication Date
WO2005120493A1 true WO2005120493A1 (en) 2005-12-22
WO2005120493A8 WO2005120493A8 (en) 2007-03-22

Family

ID=34970391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/011078 Ceased WO2005120493A1 (en) 2004-06-10 2005-06-10 Anticancer effect enhancer

Country Status (8)

Country Link
US (2) US20080039521A1 (https=)
EP (1) EP1778215B1 (https=)
JP (2) JP4729503B2 (https=)
KR (1) KR20070045187A (https=)
CN (1) CN101001623B (https=)
DE (1) DE602005018222D1 (https=)
ES (1) ES2338022T3 (https=)
WO (1) WO2005120493A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010024170A (ja) * 2008-07-17 2010-02-04 Hiroshi Maeda 抗悪性腫瘍剤の腫瘍組織への局所送達増強剤
EP2334279A4 (en) * 2008-10-16 2013-03-20 Novan Inc STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
US9050070B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603495B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US20100111857A1 (en) * 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8603494B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8485861B2 (en) * 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9060931B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US20100111834A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8798932B2 (en) * 2008-10-31 2014-08-05 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US9060934B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111831A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9060926B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8725420B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731841B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) * 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9072799B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111841A1 (en) * 2008-10-31 2010-05-06 Searete Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8793075B2 (en) * 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8721583B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111836A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111835A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
BR112012008508A2 (pt) * 2009-10-13 2017-06-13 Novan Inc revestimento de sol-gel, substrato, método para produzir um revestimento de sol-gel
CN102107009A (zh) * 2009-12-25 2011-06-29 奇复康药物研发(苏州)有限公司 天然药物组分和一氧化氮供体的混合复方药物及其用途
JP5842367B2 (ja) * 2011-04-07 2016-01-13 ニプロ株式会社 抗癌剤増感剤
WO2012154975A2 (en) * 2011-05-11 2012-11-15 Stc.Unm Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion
CN103130815B (zh) * 2013-02-07 2015-10-07 浙江工业大学 一种单硝酸异山梨酯衍生物及其制备方法和应用
JP6516723B2 (ja) 2014-02-20 2019-05-22 浩文 山本 抗癌剤の抗腫瘍効果の増強剤
JP6543612B2 (ja) 2014-03-04 2019-07-10 浩文 山本 大腸癌の治療剤、及び大腸癌患者の予後の予測方法
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
CN107823644B (zh) * 2017-11-07 2021-03-02 福州大学 一种no供体化合物在制备抑制富含巯基分子的肿瘤细胞的侵袭和转移能力药物中的应用
CN109498818B (zh) * 2018-05-25 2021-08-31 福州大学 一种产生NO的pH敏感脂质体及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074082A1 (en) * 2002-03-06 2003-09-12 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics in cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU685178B2 (en) * 1993-10-08 1998-01-15 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
IT1282686B1 (it) * 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
JP2004508279A (ja) 2000-01-26 2004-03-18 シーダース　シナイ　メディカル　センター 薬剤を異常脳領域及び／又は悪性腫瘍にデリバリーするためにカリウムチャンネル活性化を用いる方法
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20020173538A1 (en) * 2000-06-30 2002-11-21 Ming-Shi Shiao Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074082A1 (en) * 2002-03-06 2003-09-12 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics in cancer treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JORDAN BENEDICTE F ET AL: "Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSAII murine tumors.", INTERNATIONAL JOURNAL OF CANCER, vol. 103, no. 1, 1 January 2003 (2003-01-01), pages 138 - 141, XP002341965, ISSN: 0020-7136 *
PIPILI-SYNETOS E ET AL: "INHIBITION OF ANGIOGENESIS, TUMOUR GROWTH AND METASTASIS BY THE NO-RELEASING VASODILATORS, ISOSORBIDE MONONITRATE AND DINITRATE", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 116, no. 2, September 1995 (1995-09-01), pages 1829 - 1834, XP001064188, ISSN: 0007-1188 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403852B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8956658B2 (en) 2005-05-27 2015-02-17 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8962029B2 (en) 2005-05-27 2015-02-24 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US11691995B2 (en) 2005-05-27 2023-07-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403851B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US11583608B2 (en) 2009-08-21 2023-02-21 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US9737561B2 (en) 2009-08-21 2017-08-22 Novan, Inc. Topical gels and methods of using the same
US10376538B2 (en) 2009-08-21 2019-08-13 Novan, Inc. Topical gels and methods of using the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US9713652B2 (en) 2011-02-28 2017-07-25 The University Of North Carolina At Chapel Hill Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same

Also Published As

Publication number Publication date
EP1778215A1 (en) 2007-05-02
JP4729503B2 (ja) 2011-07-20
DE602005018222D1 (https=) 2010-01-21
ES2338022T3 (es) 2010-05-03
KR20070045187A (ko) 2007-05-02
EP1778215B1 (en) 2009-12-09
JP2008501630A (ja) 2008-01-24
CN101001623A (zh) 2007-07-18
JP2011144190A (ja) 2011-07-28
WO2005120493A8 (en) 2007-03-22
US20090137683A1 (en) 2009-05-28
US20080039521A1 (en) 2008-02-14
US8410175B2 (en) 2013-04-02
CN101001623B (zh) 2010-11-17

Similar Documents

Publication Publication Date Title
US8410175B2 (en) Anticancer effect enhancer
JP2008501630A6 (ja) 抗癌剤の効果増強剤
Choy et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non–small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)
Ajani et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
US12102613B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Spalding et al. New and emerging radiosensitizers and radioprotectors
Kaira et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
Franciosi et al. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients
Pershing et al. Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer
Mason et al. Biology-based combined-modality radiotherapy: workshop report
Poggi et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer
Celio et al. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study
Meyer et al. A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer
William Jr et al. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer
Aghajanian et al. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer
Misirliogluo et al. Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer: a randomized prospective clinical trial
Jeremić et al. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients
Kim et al. A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer
Messersmith et al. 588 A first-in-patient phase I study of the novel gamma secretase inhibitor PF-03084014 in patients with advanced solid tumor malignancies
Garces et al. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer
Lochrin et al. Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer
CA2557857C (en) Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
EP4093398B1 (en) Abt-751 and ionizing radiation for use in treating a brain tumor
Pergolizzi et al. Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study
Paller et al. Vitamin C and Cancer: An Overview of Recent Clinical Trials

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006551137

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005750803

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077000537

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580027168.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11628943

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005750803

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11628943

Country of ref document: US